@entity2015 in XXXX in the United States.

@entity1 @entity1593 @entity1109 @entity344 @entity7491 @entity74 @entity792 @entity2015
BACKGROUND AND AIMS: Multiple European studies report increased prevalence of selective @entity2015 (SIgAD) and partial @entity2015 (PIgAD) in @entity1593 ( @entity1593 ) @entity1 . However; prospective data representing North American adults are lacking. While SIgAD precludes the use of IgA-tissue-transglutaminase antibody (IgA-tTG), the effect of PIgAD on IgA-tTG sensitivity is not well documented. We aim to determine the prevalence and impact of @entity7491 on @entity1593 presentation and diagnosis in North American adult @entity1 . METHODS: We reviewed 1000 consecutive @entity1 undergoing IgA-tTG testing and 243 healthy controls. Eligible sera were tested for IgA-tTG, serum immunoglobulins and IgA/IgG-Deamidated Gliadin Peptide (IgA/IgG-DGP). RESULTS: Prevalence of SIgAD was marginally higher in @entity1593 @entity1 (1.9%) compared with healthy controls (0.4%, p   =   0.24) and non- @entity1593 @entity1 (0.7% p   =   0.173). Prevalence of PIGAD was similar in @entity1593 @entity1 (4.8%) compared with healthy controls (5.9% p   =   0.57) and non- @entity1593 @entity1 (7.2% p   =   0.22). 1 (16.7%) of 6 @entity1593 @entity1 with SIgAD and all 15 (100%) with PIGAD tested IgA-tTG positive prior to GFD initiation. @entity1593 @entity1 with SIGAD showed lower frequency of @entity1109 (33% vs 82% p   =   0.01) and more co-morbid @entity792 (67% vs 23% p   =   0.03) when compared to @entity1593 @entity1 with normal IgA. CONCLUSIONS: The prevalence of SIgAD in North American @entity1593 @entity1 is comparable with European data but not significantly different than control populations. @entity1593 @entity1 with SIgAD exhibit decreased IgA-tTG sensitivity and lack of @entity344 . PIgAD is common in @entity1 with @entity74 but does not alter @entity1593 presentation or IgA-tTG sensitivity.
